Workflow
LivaNova(LIVN)
icon
Search documents
LivaNova(LIVN) - 2024 Q3 - Earnings Call Transcript
2024-10-30 18:30
LivaNova PLC (NASDAQ:LIVN) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Matthew Dodds - Senior Vice President-Corporate Development & IT Vladimir Makatsaria - Chief Executive Officer Ahmet Tezel - Chief Innovation Officer Alex Shvartsburg - Chief Financial Officer Stephanie Bolton - President, Global Epilepsy Conference Call Participants David Roman - Goldman Sachs Rick Wise - Stifel David Rescott - Baird Michael Pollack - Wolfe Research Adam Maeder - Piper Sandler Antho ...
LivaNova(LIVN) - 2024 Q3 - Earnings Call Presentation
2024-10-30 15:28
| --- | --- | --- | --- | --- | |------------------------------|-------|-------|-------|-------| | | | | | | | Liva Nova Third-Quarter 2024 | | | | | | Earnings Update | | | | | | October 30, 2024 | | | | | Safe Harbor 2 Certain statements in this material, other than statements of historical or current fact, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange Act. These statements inc ...
LivaNova (LIVN) Tops Q3 Earnings and Revenue Estimates
ZACKS· 2024-10-30 12:15
LivaNova (LIVN) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.73 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 26.76%. A quarter ago, it was expected that this medical technology company would post earnings of $0.79 per share when it actually produced earnings of $0.93, delivering a surprise of 17.72%. Over the last four quarters, ...
LivaNova(LIVN) - 2024 Q3 - Quarterly Results
2024-10-30 10:03
EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Third-Quarter 2024 Results London, October 30, 2024 – LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended September 30, 2024 and raised full-year 2024 guidance. Financial Summary and Highlights (1) • Third-quarter revenue of $318.1 million increased 11.2% on both a reported and constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (AC ...
LivaNova: Economics Should Start Making Sustained Improvements
Seeking Alpha· 2024-10-18 07:45
If you thought our angle on this company was interesting, you may want to check out our idea room, The Value Lab . We focus on long-only value ideas of interest to us, where we try to find international mispriced equities and target a portfolio yield of about 4% . We've done really well for ourselves over the last 5 years, but it took getting our hands dirty in international markets. If you are a value-investor, serious about protecting your wealth, our gang could help broaden your horizons and give some in ...
LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts
Benzinga· 2024-10-04 15:59
Shares of LivaNova Plc LIVN Tuesday climbed along with several other big stocks. There is high visibility into the company's near-term baseline growth, with potential upside to revenue and earnings from "new product cycles and pipeline optionality," according to Goldman Sachs. Analyst David Roman initiated coverage of LivaNova with a Buy rating and price target of $65. The LivaNova Thesis: LivaNova's earnings had been under pressure due to strategic shifts in the company's business and pipeline setbacks. Ro ...
LivaNova(LIVN) - 2024 Q2 - Quarterly Report
2024-08-01 20:23
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number: 001-37599 LivaNova PLC (Exact name of registrant as specified in its char ...
LivaNova(LIVN) - 2024 Q2 - Earnings Call Transcript
2024-07-31 17:57
LivaNova PLC (NASDAQ:LIVN) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET Company Participants Matthew Dodds – Senior Vice President-Corporate Development and IT Vladimir Makatsaria – Chief Executive Officer Alex Shvartsburg – Chief Financial Officer Ahmet Tezel – Chief Innovation Officer Conference Call Participants Rick Wise – Stifel Mike Sarcone – Jefferies Michael Polark – Wolfe Research Adam Maeder – Piper Sandler Anthony Petrone – Mizuho Group Mike Matson – Needham & Company David Rescott – ...
LivaNova(LIVN) - 2024 Q2 - Earnings Call Presentation
2024-07-31 15:30
Adjusted Gross Profit % Adjusted SG&A % Adjusted R&D % Adjusted R&D % $318.6• Net revenue increased 9.6 percent on a constant-currency basis • Foreign currency had an unfavorable impact on net revenue of ~$3M, or approximately 1 percent Adjusted Operating Margin % Note: Net revenue, total revenue excluding revenue from the ACS segment wind down, adjusted diluted EPS and adjusted gross profit, adjusted SG&A, adjusted R&D, and adjusted operating margin all as a percentage of net revenue are non-GAAP measures. ...
LivaNova (LIVN) Beats Q2 Earnings and Revenue Estimates
ZACKS· 2024-07-31 12:10
LivaNova (LIVN) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.79 per share. This compares to earnings of $0.78 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 17.72%. A quarter ago, it was expected that this medical technology company would post earnings of $0.45 per share when it actually produced earnings of $0.73, delivering a surprise of 62.22%. Over the last four quarters, ...